HMGCR and Alzheimer disease: Then they performed a meta-analysis of Mendelian randomization estimates for LDL-C-weighted regional variants on Alzheimer’s disease (AD) risk from 2 large samples and found that the HMGCR and NPC1L1 models did not indicate that the use of related lipid-lowering drug classes would affect the risk for AD [78].